EX-99.1 2 d221299dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO   News Release

CORRECTING and REPLACING AstroNova Reports Fiscal 2025 Fourth-Quarter and Full-Year Financial Results; Advancing Restructuring, Operational Realignment and Product Simplification Plans to Drive Improved Earnings Power

CORRECTION...by AstroNova

WEST WARWICK, R.I.—(BUSINESS WIRE)—The Condensed Consolidated Statements of Cash Flows and Reconciliation of GAAP to Non-GAAP Items for PI Segment tables of release dated April 14, 2025 have been updated.

The updated release reads:

AstroNova Reports Fiscal 2025 Fourth-Quarter and Full-Year Financial Results; Advancing Restructuring, Operational Realignment and Product Simplification Plans to Drive Improved Earnings Power

 

   

Fourth quarter revenue of $37.4 million in line with preliminary expectations; fiscal 2025 revenue of $151.3 million comprised of 71% recurring revenue

 

   

Restructuring plan expected to deliver $3 million in annualized savings with 40% to be realized in fiscal 2026

 

   

Simplifying product portfolio; focused on higher growth higher margin products

 

   

Aerospace Test & Measurement segment ToughWriter printer transition 40% complete; drives operational efficiency and reduced working capital requirements while eliminating legacy royalties

West Warwick, R.I., April 14, 2025 – AstroNova, Inc. (Nasdaq: ALOT), a global leader in data visualization technologies, today announced financial results for its fiscal 2025 fourth quarter and full-year ended January 31, 2025. Results include the May 6, 2024 acquisition of MTEX NS.

Greg Woods, President and Chief Executive Officer of AstroNova, stated, “Fiscal 2025 was a challenging year as we addressed the difficult integration of MTEX, absorbed the impact of the Boeing strike and addressed the timing associated with large defense industry orders. Nonetheless, we aggressively implemented the AstroNova Operating System at MTEX, improved the leadership team, upgraded talent within the organization, and significantly improved the accounting and finance system and human resources processes. We are instilling accountability and discipline into the organization, streamlining the structure and eliminating waste. We have also identified how to best leverage MTEX’s operations in Portugal to create an AstroNova Center of Manufacturing Excellence in Europe. In fact, we are taking action throughout AstroNova to create a business that can deliver stronger earnings power.”

 

1


“Importantly, we are leveraging the innovative foundation of MTEX technologies to create more competitive solutions that address an expanded range of applications and provide our customers with higher quality and reliability. This will also enable us to gain greater control over our supply chain in order to reduce costs and expand margins. We plan to launch new products incorporating our next-generation technology in the first quarter of fiscal 2026 and will be rolling out more products throughout the year.”

Fiscal 2026 Outlook Reaffirmed

For fiscal 2026, AstroNova continues to expect net revenue in the range of $160 million to $165 million which is a 7% increase over fiscal 2025 at the mid-point of the range. Adjusted EBITDA margin is expected to be in the range of 8.5% to 9.5%, a 60-basis point expansion over the prior year at the mid-point.

Mr. Woods added, “We are focused on innovative solutions to gain market share and expand our market reach. Our strategic priorities in fiscal 2026 are to drive our print engine technology initiatives, capture greater ownership of the supply chain for our consumables, and drive the conversion to our ToughWriter family of printers with our Aerospace customers. In addition to offering a better solution for our customers, this conversion and other product simplification initiatives will reduce inventory, improve working capital and drive profitability.”

Fourth Quarter Fiscal 2025 Overview

Net revenue for the fourth quarter of fiscal 2025 was $37.4 million compared with net revenue of $39.6 million for the fourth quarter of fiscal 2024, a decrease of 5.6% or $2.2 million, reflecting lower sales in both Product Identification (PI) and Test & Measurement (T&M) segments.

PI revenue was $25.7 million for the fourth quarter of fiscal 2025 compared with $26.6 million for the fourth quarter of fiscal 2024, a decrease of 3.6% or $0.9 million. The decrease was primarily attributable to less favorable product mix in the 2025 period, partially offset by the addition of MTEX, which the Company acquired in May 2024.

On a GAAP (Generally Accepted Accounting Principles) basis, PI segment operating loss was $11.2 million for the fourth quarter of fiscal 2025, which includes the previously announced non-cash goodwill impairment of $13.4 million largely associated with the Company’s MTEX business and $0.1 million in inventory step-up expenses. This compares with PI segment GAAP operating profit of $3.2 million, or 12.2% of segment revenue, for the fourth quarter of fiscal 2024, which includes $0.3 million in product retrofit costs and restructuring charges. On a non-GAAP basis, excluding the discrete expenses in both periods, PI segment operating profit was $2.3 million, or 8.9% of segment revenue in the fourth quarter of fiscal 2025, compared with segment operating profit of $3.0 million, or 11.1% of segment revenue, for the fourth quarter of fiscal 2024.

T&M segment revenue was $11.7 million for the fourth quarter of fiscal 2025 compared with $13.0 million for the fourth quarter of fiscal 2024, a decrease of 9.9% or $1.3 million. The decrease was due primarily to a delayed defense order and, to a lesser extent, deferred deliveries associated with the Boeing strike.

 

2


T&M segment operating profit was $2.3 million, or 20.0% of segment revenue, for the fourth quarter of fiscal 2025 compared with segment operating profit of $3.7 million, or 28.2% of segment revenue, for the fourth quarter of fiscal 2024.

GAAP gross profit was $12.7 million for the fourth quarter of fiscal 2025, resulting in a gross margin of 34.1%, compared with gross profit of $14.7 million and a gross profit of 37.2% for the same period in fiscal 2024, primarily reflecting lower revenue and less favorable product mix in the 2025 period.

GAAP operating loss for the fourth quarter of fiscal 2025 was $12.3 million, compared with GAAP operating income of $3.9 million for the fourth quarter of fiscal 2024. On a non-GAAP basis, excluding discrete items in both periods, the Company reported operating income of $1.4 million, compared with $3.6 million in the fourth quarter of fiscal 2024.

Net loss on a GAAP basis was $15.6 million, or $2.07 per share, for the fourth quarter of fiscal 2025 compared with net income of $2.7 million, or $0.36 per diluted share, for the fourth quarter of fiscal 2024. On a non-GAAP basis, excluding discrete items in both periods, the Company reported net income of $0.4 million, or $0.06 per diluted share, for the fourth quarter of fiscal 2025 compared with net income of $2.5 million, or $0.33 per diluted share, in the fourth quarter of fiscal 2024.

Adjusted EBITDA was $2.8 million for the fourth quarter of fiscal 2025 compared with Adjusted EBITDA $5.2 million for the fourth quarter of fiscal 2024.

The Company’s order backlog was $28.3 million as of January 31, 2025 compared with $31.4 million at the end of fiscal 2024.

Full-Year Fiscal 2025 Overview

Net revenue for fiscal 2025 was $151.3 million compared with net revenue of $148.1 million for fiscal 2024, an increase of 2.2% or $3.2 million, reflecting higher sales in the T&M segment, partially offset by lower sales in the PI segment.

PI revenue was $102.3 million for fiscal 2025 compared with $104.0 million for fiscal 2024, a decrease of 1.6% or $1.7 million. The decrease was primarily attributable to less favorable product mix in the 2025 period, partially offset by the addition of MTEX, which the Company acquired in May 2024.

On a GAAP (Generally Accepted Accounting Principles) basis, PI segment operating loss was $4.0 million for fiscal 2025, which includes the previously announced non-cash goodwill impairment of $13.4 million largely associated with the Company’s MTEX business and $0.2 million in inventory step-up expenses. This compares with PI segment GAAP operating profit of $10.1 million, or 9.7% of segment revenue, for fiscal 2024, which includes $3.2 million in product retrofit costs and restructuring charges. On a non-GAAP basis, excluding the discrete expenses in both periods, PI segment operating profit was $9.7 million, or 9.4% of segment revenue, for fiscal 2025, compared with segment operating profit of $13.2 million, or 12.7% of segment revenue, for fiscal 2024.

 

3


T&M segment revenue was $48.9 million for fiscal 2025 compared with $44.0 million fiscal 2024, an increase of 11.1% or $4.9 million. The increase primarily reflected higher revenue from supplies and service/other in the 2025 period, partly offset by lower hardware sales.

T&M segment operating profit was $11.1 million, or 22.8% of segment revenue, fiscal 2025 compared with segment operating profit of $10.2 million, or 23.2% of segment revenue, for fiscal 2024.

GAAP gross profit was $52.7 million for fiscal 2025, resulting in a gross margin of 34.9%, compared with gross profit of $51.6 million and a gross profit of 34.9% for fiscal 2024.

GAAP operating loss for fiscal 2025 was $8.6 million, compared with GAAP operating income of $8.8 million for fiscal 2024. On a non-GAAP basis, excluding discrete items in both periods, the Company reported operating income of $6.6 million for fiscal 2025, compared with $12.0 million for fiscal 2024, primarily related to higher operating expenses in the 2025 period.

Net loss on a GAAP basis was $14.5 million, or $1.93 per share, for fiscal 2025 compared with net income of $4.7 million, or $0.63 per diluted share, for fiscal 2024. On a non-GAAP basis, excluding discrete items in both periods, the Company reported net income of $2.7 million, or $0.33 per diluted share, in fiscal 2025 compared with net income of $7.2 million, or $0.97 per diluted share, in fiscal 2024.

Adjusted EBITDA was $12.3 million for fiscal 2025 compared with Adjusted EBITDA $17.6 million for fiscal 2024.

Amendment and Waiver of Credit Agreement

As previously disclosed, AstroNova obtained an amendment and waiver with regard to its credit agreement with Bank of America. Among other changes to the credit agreement, the amendment waives certain covered covenants as of the end of its fiscal quarter ended January 31, 2025, provides for relaxed financial covenant ratios during fiscal 2026, and provides for reduced payments of one of its term loans during fiscal 2026 as the Company implements its restructuring efforts, after which the payments of such term loan increase. The amended credit agreement provides for up to $2 million in add-backs to the Company’s Consolidated EBITDA (as defined in the credit agreement) for Company cash restructuring charges in fiscal 2026.

Earnings Conference Call Information

AstroNova will discuss its fiscal fourth-quarter and full-year fiscal 2025 financial results and business outlook in an investor conference call at 9:00 a.m. ET today. To access the conference call, please dial (833) 470-1428 (U.S. and Canada) or (404) 975-4839 (International) approximately 10 minutes prior to the start time and enter access code 957215.

A real-time and an archived audio webcast of the call will be available through the “Investors” section of the AstroNova website, https://investors.astronovainc.com.

 

4


Use of Non-GAAP Financial Measures

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this news release contains the non-GAAP financial measures non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income, non-GAAP net income per diluted share, non-GAAP segment operating profit, and Adjusted EBITDA. AstroNova believes that the inclusion of these non-GAAP financial measures helps investors gain a meaningful understanding of changes in the Company’s core operating results and can help investors who wish to make comparisons between AstroNova and other companies on both a GAAP and a non-GAAP basis. AstroNova’s management uses these non-GAAP financial measures, in addition to GAAP financial measures, as the basis for measuring its core operating performance and comparing such performance to that of prior periods and to the performance of its competitors. These measures are also used by the Company’s management to assist with their financial and operating decision-making. Please refer to the financial reconciliation table included in this news release for a reconciliation of the non-GAAP measures to the most directly comparable GAAP measures for the three and 12 months ended January 31, 2025 and 2024.

AstroNova has not reconciled the forward-looking Adjusted EBITDA growth percentage included in its fiscal 2026 financial targets and outlook to the most directly comparable forward-looking GAAP measure because this cannot be done without unreasonable effort due to the lack of predictability regarding cost of sales, operating expenses, depreciation and amortization, and stock-based compensation. The impact of any of these items, individually or in the aggregate, may be significant.

About AstroNova

AstroNova (Nasdaq: ALOT), a global leader in data visualization technologies since 1969, designs, manufactures, distributes and services a broad range of products that acquire, store, analyze, and present data in multiple formats.

The Product Identification segment provides a wide array of digital, end-to-end product marking and identification solutions, including hardware, software, and supplies for OEMs, commercial printers, and brand owners. The Test and Measurement segment provides products designed for airborne printing solutions, avionics, and data acquisition. Our aerospace products include flight deck printing solutions, networking hardware, and specialized aerospace-grade supplies. Our data acquisition systems are used in research and development, flight testing, missile and rocket telemetry production monitoring, power, and maintenance applications.

AstroNova is a member of the Russell Microcap® Index and the LD Micro Index (INDEXNYSEGIS: LDMICRO). Additional information is available by visiting https://astronovainc.com/.

Forward-Looking Statements

Information included in this news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact but rather reflect our current expectations concerning future events and results. These statements may include the use of the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “continues,” “may,” “will,” and similar expressions to identify forward-looking statements.

 

5


Such forward-looking statements, including those concerning the Company’s anticipated performance, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, (i) the risk that our organizational improvements at MTEX may not result in the benefits that we expect; (ii) the risk that our cost-reduction and product line rationalization initiative may not provide the expected benefits; (iii) the risk that our Aerospace customers may not convert to our ToughWriter line in the volumes or on the schedule that we expect; (iv) the risk that we may not realize the anticipated benefits of our next-generation print engine technology; and (v) those factors set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended January 31, 2024 and subsequent filings AstroNova makes with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The reader is cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this news release.

Contacts:

Tom DeByle

Vice President, Chief Financial Officer & Treasurer

AstroNova, Inc.

(401) 828-4000

Scott Solomon

Senior Vice President

Sharon Merrill Advisors

(857) 383-2409

[email protected]

 

6


ASTRONOVA, INC.

Condensed Consolidated Statements of Income

In Thousands Except for Per Share Data

(Unaudited)

 

     Three Months Ended  
     January 31,
2025
    January 31,
2024
 

Net Revenue

   $ 37,361     $ 39,594  

Cost of Revenue

     24,624       24,848  
  

 

 

   

 

 

 

Gross Profit

     12,737       14,746  

Total Gross Profit Margin

     34.1     37.2

Operating Expenses:

    

Selling & Marketing

     6,421       5,977  

Research & Development

     1,751       1,878  

General & Administrative

     3,473       2,976  

Goodwill Impairment

     13,403       —   
  

 

 

   

 

 

 

Total Operating Expenses

     25,048       10,831  

Operating Income (Loss)

     (12,311     3,915  

Total Operating Margin

     (33.0 )%      9.9

Interest Expense

     847       779  

Other (Income)/Expense, net

     100       (216
  

 

 

   

 

 

 

Income (Loss) Before Taxes

     (13,258     3,352  

Income Tax Provision

     2,342       641  
  

 

 

   

 

 

 

Net Income (Loss)

   $ (15,600   $ 2,711  
  

 

 

   

 

 

 

Net Income (Loss) per Common Share - Basic

   $ (2.07   $ 0.36  
  

 

 

   

 

 

 

Net Income (Loss) per Common Share - Diluted

   $ (2.07   $ 0.36  
  

 

 

   

 

 

 

Weighted Average Number of Common Shares - Basic

     7,534       7,438  

Weighted Average Number of Common Shares - Diluted

     7,534       7,550  
     Twelve Months Ended  
     January 31,
2025
    January 31,
2024
 

Net Revenue

   $ 151,283     $ 148,086  

Cost of Revenue

     98,534       96,465  
  

 

 

   

 

 

 

Gross Profit

     52,749       51,621  

Total Gross Profit Margin

     34.9     34.9

Operating Expenses:

    

Selling & Marketing

     25,560       24,428  

Research & Development

     6,610       6,906  

General & Administrative

     15,816       11,491  

Goodwill Impairment

     13,403       —   
  

 

 

   

 

 

 

Total Operating Expenses

     61,389       42,825  

Operating Income (Loss)

     (8,640     8,796  

Total Operating Margin

     (5.7 )%      5.9

Interest Expense

     3,210       2,697  

Other (Income)/Expense, net

     437       26  
  

 

 

   

 

 

 

Income (Loss) Before Taxes

     (12,287     6,073  

Income Tax Provision

     2,202       1,379  
  

 

 

   

 

 

 

Net Income (Loss)

   $ (14,489   $ 4,694  
  

 

 

   

 

 

 

Net Income (Loss) per Common Share - Basic

   $ (1.93   $ 0.63  
  

 

 

   

 

 

 

Net Income (Loss) per Common Share - Diluted

   $ (1.93   $ 0.63  
  

 

 

   

 

 

 

Weighted Average Number of Common Shares - Basic

     7,509       7,415  

Weighted Average Number of Common Shares - Diluted

     7,509       7,496  

 

7


ASTRONOVA, INC.

Consolidated Balance Sheets

In Thousands

(Unaudited)

 

     January 31,
2025
    January 31,
2024
 

ASSETS

    

CURRENT ASSETS

    

Cash and Cash Equivalents

   $ 5,050     $ 4,527  

Accounts Receivable, net

     21,218       23,056  

Inventories, net

     47,894       46,371  

Prepaid Expenses and Other Current Assets

     3,855       2,720  
  

 

 

   

 

 

 

Total Current Assets

     78,017       76,674  

PROPERTY, PLANT AND EQUIPMENT

     62,361       57,046  

Less Accumulated Depreciation

     (44,722     (42,861
  

 

 

   

 

 

 

Property, Plant and Equipment, net

     17,639       14,185  

OTHER ASSETS

    

Intangible Assets, net

     23,519       18,836  

Goodwill

     14,515       14,633  

Deferred Tax Assets

     8,431       6,882  

Right of Use Asset

     1,781       603  

Other Assets

     1,694       1,438  
  

 

 

   

 

 

 

TOTAL ASSETS

   $ 145,595     $ 133,251  
  

 

 

   

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

    

CURRENT LIABILITIES

    

Accounts Payable

   $ 7,928     $ 8,068  

Accrued Compensation

     3,745       2,923  

Other Liabilities and Accrued Expenses

     4,461       2,706  

Revolving Line of Credit

     20,929       8,900  

Current Portion of Long-Term Debt

     6,110       2,842  

Short-Term Debt

     581       —   

Current Portion of Royalty Obligation

     1,358       1,700  

Current Liability – Excess Royalty Payment Due

     691       935  

Income Taxes Payable

     (0     349  

Deferred Revenue

     543       1,338  
  

 

 

   

 

 

 

Total Current Liabilities

     46,346       29,761  

NON-CURRENT LIABILITIES

    

Long-Term Debt, net of current portion

     19,044       10,050  

Royalty Obligation, net of current portion

     1,106       2,093  

Lease Liability, net of current portion

     1,535       415  

Grant Deferred Revenue

     1,090       —   

Income Tax Payables

     684       551  

Deferred Tax Liabilities

     40       99  
  

 

 

   

 

 

 

TOTAL LIABILITIES

     69,845       42,969  

SHAREHOLDERS’ EQUITY

    

Common Stock

     547       541  

Additional Paid-in Capital

     64,215       62,684  

Retained Earnings

     49,380       63,869  

Treasury Stock

     (35,043     (34,593

Accumulated Other Comprehensive Loss, net of tax

     (3,349     (2,219
  

 

 

   

 

 

 

TOTAL SHAREHOLDERS’ EQUITY

     75,750       90,282  
  

 

 

   

 

 

 

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

   $ 145,595     $ 133,251  
  

 

 

   

 

 

 

 

8


ASTRONOVA, INC.

Condensed Consolidated Statements of Cash Flows

(In Thousands)

(Unaudited)

 

     Twelve Months Ended  
     January 31, 2025     January 31, 2024  

Cash Flows from Operating Activities:

    

Net Income (Loss)

   $ (14,489   $ 4,694  

Adjustments to Reconcile Net Income (Loss) to Net Cash Provided by Operating

    

Activities:

    

Depreciation and Amortization

     4,780       4,266  

Grant Income Charged to Depreciation

     159        

Goodwill Impairment

     13,403        

Amortization of Debt Issuance Costs

     30       23  

Restructuring Cost

           2,040  

Share-Based Compensation

     1,378       1,347  

Deferred Income Tax provision (Benefit)

     874       (78

Changes in Assets and Liabilities, net of impact of acquisition:

    

Accounts Receivable

     2,859       (1,486

Inventories

     1,616       2,910  

Accounts Payable and Accrued Expenses

     (2,379     (46

Deferred Revenue

     (1,520      

Income Taxes

     (904     (343

Other

     (959     (973
  

 

 

   

 

 

 

Net Cash Provided by Operating Activities

     4,848       12,354  

Cash Flows from Investing Activities:

    

Purchases of Property, Plant and Equipment

     (1,165     (875

Cash Paid for MTEX Acquisition, net of cash acquired

     (19,109      
  

 

 

   

 

 

 

Net Cash Provided (Used) for Investing Activities

     (20,274     (875

Cash Flows from Financing Activities:

    

Net Cash Proceeds from Employee Stock Option Plans

     13       105  

Net Cash Proceeds from Share Purchases under Employee Stock Purchase Plan

     146       107  

Net Cash Used for Payment of Taxes Related to Vested Restricted Stock

     (450     (358

Net Borrowings under Revolving Credit Facility

     11,508       (7,000

Proceeds from Long-Term Debt Borrowings

     15,078        

Payment of Minimum Guarantee Royalty Obligation

     (1,902     (1,725

Principal Payments of Long-Term Debt

     (8,980     (2,100

Payments of Debt Issuance Costs

     (35      
  

 

 

   

 

 

 

Net Cash Provided (Used) for Financing Activities

     15,378       (10,971

Effect of Exchange Rate Changes on Cash and Cash Equivalents

     571       73  
  

 

 

   

 

 

 

Net Increase in Cash and Cash Equivalents

     523       581  

Cash and Cash Equivalents, Beginning of Period

     4,527       3,946  
  

 

 

   

 

 

 

Cash and Cash Equivalents, End of Period

   $ 5,050     $ 4,527  
  

 

 

   

 

 

 

Supplemental Disclosures of Cash Flow Information:

    

Cash Paid During the Period for:

    

Cash Paid During the Period for Interest

   $ 2,701     $ 2,343  

Cash Paid During the Period for Income Taxes, net of refunds

   $ 2,210     $ 1,694  

Non-Cash Transactions:

    

Financed Equipment Purchase

   $ —      $ 822  

Capital Lease Obtained in Exchange for Capital Lease Liabilities

   $ 1,581     $ —   

 

9


ASTRONOVA, INC.

Revenue and Segment Operating Profit

In Thousands

(Unaudited)

 

     Revenue      Segment Operating
Profit
 
     Three Months Ended      Three Months Ended  
     January 31,
2025
     January 31,
2024
     January 31,
2025
    January 31,
2024
 

Product Identification

   $ 25,679      $ 26,626      $ (11,174   $ 3,239  

Test & Measurement

     11,683        12,968        2,337       3,652  
  

 

 

    

 

 

    

 

 

   

 

 

 

Total

   $ 37,361      $ 39,594        (8,837     6,891  
  

 

 

    

 

 

      

General & Administrative Expenses

           3,473       2,976  
        

 

 

   

 

 

 

Operating Income (Loss)

           (12,311     3,915  

Interest Expense

           847       779  

Other (Income)/Expense, net

           100       (216
        

 

 

   

 

 

 

Income (Loss) Before Income Taxes

           (13,258     3,352  

Income Tax Provision

           2,342       641  
        

 

 

   

 

 

 

Net Income (Loss)

         $ (15,600   $ 2,711  
        

 

 

   

 

 

 
     Revenue      Segment Operating
Profit
 
     Twelve Months Ended      Twelve Months Ended  
     January 31,
2025
     January 31,
2024
     January 31,
2025
    January 31,
2024
 

Product Identification

   $ 102,345      $ 104,041      $ (3,967   $ 10,087  

Test & Measurement

     48,938        44,045        11,143       10,200  
  

 

 

    

 

 

    

 

 

   

 

 

 

Total

   $ 151,283      $ 148,086        7,176       20,287  
  

 

 

    

 

 

      

General & Administrative Expenses

           15,816       11,491  
        

 

 

   

 

 

 

Operating Income (Loss)

           (8,640     8,796  

Interest Expense

           3,210       2,697  

Other (Income)/Expense, net

           437       26  
        

 

 

   

 

 

 

Income (Loss) Before Income Taxes

           (12,287     6,073  

Income Tax Provision

           2,202       1,379  
        

 

 

   

 

 

 

Net Income (Loss)

         $ (14,489   $ 4,694  
        

 

 

   

 

 

 

Note: Segment Operating Profit excludes General & Administrative Expenses

 

10


ASTRONOVA, INC.

Reconciliation of GAAP to Non-GAAP Items

In Thousands Except for Per Share Data

(Unaudited)

 

     Three Months Ended  
     January 31,
2025
    January 31,
2024
 

Gross Profit

   $ 12,737     $ 14,746  

Inventory Step-Up

     62       —   

Restructuring Charges, net

     —        (32

Product Retrofit Costs, net

     —        (210
  

 

 

   

 

 

 

Non-GAAP Gross Profit

   $ 12,799     $ 14,504  
  

 

 

   

 

 

 

Operating Expenses

   $ 25,048     $ 10,831  

MTEX-related Acquisition Expenses

     (254     0  

Restructuring Charges, net

     —        43  

Goodwill Impairment

     (13,403     —   
  

 

 

   

 

 

 

Non-GAAP Operating Expenses

   $ 11,392     $ 10,874  
  

 

 

   

 

 

 

Operating Income (Loss)

   $ (12,311   $ 3,915  

MTEX-related Acquisition Expenses

     254       (0

Inventory Step-Up

     62       —   

Restructuring Charges, net

     —        (75

Product Retrofit Costs, net

     —        (210

Goodwill Impairment

     13,403       —   
  

 

 

   

 

 

 

Non-GAAP Operating Income

   $ 1,408     $ 3,630  
  

 

 

   

 

 

 

Net Income (Loss)

   $ (15,600   $ 2,711  

MTEX-related Acquisition Expenses, net

     197       (0

CFO Transition Costs, net

     (4  

Inventory Step-Up, net

     50       —   

Restructuring Charges, net

     —        (58

Product Retrofit Costs, net

     —        (162

Goodwill Impairment

     13,403       —   

Tax Provision Valuation Allowance

     2,373    
  

 

 

   

 

 

 

Non-GAAP Net Income

   $ 419     $ 2,491  
  

 

 

   

 

 

 

Diluted Earnings Per Share

   $ (2.07   $ 0.36  

MTEX-related Acquisition Expenses

     0.03       (0.00

CFO Transition Costs, net

     (0.00     —   

Inventory Step-Up

     0.01       —   

Restructuring Charges, net

     —        (0.01

Product Retrofit Costs, net

     —        (0.02

Goodwill Impairment

     1.78       —   

Tax Provision Valuation Allowance

     0.31       —   
  

 

 

   

 

 

 

Non-GAAP Diluted Earnings Per Share

   $ 0.06     $ 0.33  
  

 

 

   

 

 

 
     Twelve Months Ended  
     January 31,
2025
    January 31,
2024
 

Gross Profit

   $ 52,749     $ 51,621  

Inventory Step-Up

     216       —   

Restructuring Charges

     —        2,064  

Product Retrofit Costs

     —        642  
  

 

 

   

 

 

 

Non-GAAP Gross Profit

   $ 52,966     $ 54,327  
  

 

 

   

 

 

 

Operating Expenses

   $ 61,389     $ 42,825  

MTEX-related Acquisition Expenses

     (1,204     0  

CFO Transition Costs

     (432  

Restructuring Charges

     —        (512

Goodwill Impairment

     (13,403     —   
  

 

 

   

 

 

 

Non-GAAP Operating Expenses

   $ 46,350     $ 42,313  
  

 

 

   

 

 

 

Operating Income (Loss)

   $ (8,640   $ 8,796  

MTEX-related Acquisition Expenses

     1,204       (0

CFO Transition Costs

     432    

Inventory Step-Up

     216       —   

Restructuring Charges

     —        2,576  

Product Retrofit Costs

     —        642  

Goodwill Impairment

     13,403       —   
  

 

 

   

 

 

 

Non-GAAP Operating Income

   $ 6,615     $ 12,014  
  

 

 

   

 

 

 

Net Income (Loss)

   $ (14,489   $ 4,694  

MTEX-related Acquisition Expenses, net

     910       (0

CFO Transition Costs, net

     328       —   

Inventory Step-Up, net

     161       —   

Restructuring Charges, net

     —        1,990  

Product Retrofit Costs, net

     —        496  

Goodwill Impairment

     13,403       —   

Tax Provision

     2,373    
  

 

 

   

 

 

 

Non-GAAP Net Income

   $ 2,686     $ 7,180  
  

 

 

   

 

 

 

Diluted Earnings Per Share

   $ (1.93   $ 0.63  

MTEX-related Acquisition Expenses

     0.12       (0.00

CFO Transition Costs

     0.04       —   

Inventory Step-Up

     0.02       —   

Restructuring Charges

     —        0.27  

Product Retrofit Costs

     —        0.07  

Goodwill Impairment

     1.76       —   

Tax Provision Valuation Allowance

     0.31       —   
  

 

 

   

 

 

 

Non-GAAP Diluted Earnings Per Share

   $ 0.33     $ 0.97  
  

 

 

   

 

 

 

 

11


ASTRONOVA, INC.

Reconciliation of Net Income to Adjusted EBITDA

Amounts In Thousands

(Unaudited)

 

     Three Months Ended  
     January 31, 2025     January 31, 2024  

Net Income (Loss)

   $ (15,600   $ 2,711  

Interest Expense

     847       779  

Income Tax Expense

     2,342       641  

Depreciation & Amortization

     1,266       1,108  
  

 

 

   

 

 

 

EBITDA

   $ (11,146   $ 5,239  
  

 

 

   

 

 

 

Share-Based Compensation

     219       282  

MTEX-related Acquisition Expenses

     259       —   

CFO Transition Costs

     (5     —   

Inventory Step-Up

     62       —   

Goodwill Impairment

     13,403       —   

Restructuring Charges

     —        (75

Product Retrofit Costs

     —        (210
  

 

 

   

 

 

 

Adjusted EBITDA

   $ 2,793     $ 5,236  
  

 

 

   

 

 

 
     Twelve Months Ended  
     January 31, 2025     January 31, 2024  

Net Income (Loss)

   $ (14,489   $ 4,694  

Interest Expense

     3,210       2,697  

Income Tax Expense (Benefit)

     2,202       1,379  

Depreciation & Amortization

     4,780       4,266  
  

 

 

   

 

 

 

EBITDA

   $ (4,297   $ 13,036  
  

 

 

   

 

 

 

Share-Based Compensation

     1,378       1,347  

MTEX-related Acquisition Expenses

     1,204       —   

CFO Transition Costs

     432       —   

Inventory Step-Up

     216       —   

Goodwill Impairment

     13,403       —   

Restructuring Charges

     —        2,576  

Product Retrofit Costs

     —        642  
  

 

 

   

 

 

 

Adjusted EBITDA

   $ 12,336     $ 17,601  
  

 

 

   

 

 

 

 

12


ASTRONOVA, INC.

Reconciliation of Segment Operating Income to Non-GAAP Segment Operating Income

Amounts In Thousands

(Unaudited)

 

     Three Months Ended  
     January 31, 2025     January 31, 2024  
     Product
Identification
    Test &
Measurement
     Total     Product
Identification
    Test &
Measurement
     Total  

Segment Operating Profit (Loss)

   $ (11,174   $ 2,337      $ (8,837   $ 3,239     $ 3,652      $ 6,891  

Inventory Step-Up

     62       —         62       —        —         —   

Restructuring Charges

     —        —         —        (75     —         (75

Product Retrofit Costs

     —        —         —        (210     —         (210

Goodwill Impairment

     13,403       —         13,403       —        —         —   
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

    

 

 

 

Non-GAAP - Segment Operating Profit

   $ 2,291     $ 2,337      $ 4,628     $ 2,954     $ 3,652      $ 6,606  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

    

 

 

 
     Twelve Months Ended  
     January 31, 2025     January 31, 2024  
     Product
Identification
    Test &
Measurement
     Total     Product
Identification
    Test &
Measurement
     Total  

Segment Operating Profit (Loss)

   $ (3,967   $ 11,143      $ 7,176     $ 10,087     $ 10,200      $ 20,287  

Inventory Step-Up

     216       —         216       —        —         —   

Restructuring Charges

     —        —         —        2,494       —         2,494  

Product Retrofit Costs

     —        —         —        642       —         642  

Goodwill Impairment

     13,403       —         13,403       —        —         —   
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

    

 

 

 

Non-GAAP - Segment Operating Profit

   $ 9,652     $ 11,143      $ 20,795     $ 13,223     $ 10,200      $ 23,423  
  

 

 

   

 

 

    

 

 

   

 

 

   

 

 

    

 

 

 

Note: Segment Operating Profit excludes General & Administrative Expenses

 

13


ASTRONOVA, INC.

Reconciliation of GAAP to Non-GAAP Items for PI Segment

Amounts In Thousands

(Unaudited)

 

    Three Months Ended January 31, 2025     Three Months Ended January 31, 2024  
                            Non-GAAP                          
    Total PI
Segment as
Reported
    MTEX as
Reported
    Inventory
Step-Up
    Goodwill
Impairment
    Adj MTEX     PI Excluding MTEX     Total PI
Segment as
Reported
    Restructuring
Charges
    Product
Retrofit
Costs
    PI (Non-
GAAP)
 

Net Revenue

  $ 25,679     $ 1,657         $ 1,657     $ 24,022     $ 26,626         $ 26,626  

Cost of Revenue

    17,108       1,313       (62       1,251       15,795       17,215       75       210       17,500  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross Profit

    8,571       344       62             406       8,227       9,411       (75     (210     9,126  

Selling & Marketing

    5,439       730           730       4,709       5,121           5,121  

Research & Development

    904       198           198       706       1,051           1,051  

Goodwill Impairment

    13,403       13,403         (13,403     —        —        —            —   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating Expenses

    19,746       14,331       —        (13,403     928       5,415       6,172       —        —        6,172  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Segment Operating Profit (Loss)

  $ (11,175   $ (13,987   $ 62     $ 13,403       (522   $ 2,812     $ 3,239     $ (75   $ (210   $ 2,954  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 
    Twelve Months Ended January 31, 2025     Twelve Months Ended January 31, 2024  
                            Non-GAAP                          
    Total PI
Segment as
Reported
    MTEX as
Reported
    Inventory
Step-Up
    Goodwill
Impairment
    Adj MTEX     PI Excluding MTEX     Total PI
Segment as
Reported
    Restructuring
Charges
    Product
Retrofit
Costs
    PI (Non-
GAAP)
 

Net Revenue

  $ 102,345     $ 4,163         $ 4,163     $ 98,182     $ 104,041         $ 104,041  

Cost of Revenue

    68,420       3,652       (216       3,436       64,768       69,064       (2,494     (642     65,928  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross Profit

    33,925       511       216             727       33,414       34,977       2,494       642       38,113  

Selling & Marketing

    21,386       2,485           2,485       18,901       20,601       —          20,601  

Research & Development

    3,104       309           309       2,795       4,289       —          4,289  

Goodwill Impairment

    13,403       13,403         (13,403     —        —        0       —          0  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating Expenses

    37,893       16,197       —        (13,403     2,794       21,696       24,890       —        —        24,890  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Segment Operating Profit (Loss)

  $ (3,968   $ (15,686   $ 216     $ 13,403     $ (2,067   $ 11,718     $ 10,087     $ 2,494     $ 642     $ 13,223  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Note: Segment Operating Profit (Loss) excludes General & Administrative Expenses. MTEX General & Administrative Expenses of $411k for the three months ended January 31, 2025 and $1,194k for the twelve months ended January 31, 2025 results in Adjusted MTEX Non-GAAP Operating Loss of $933k for the three months ended January 31, 2025 and $3,261k for the twelve months ended January 31, 2025.

 

14